Top

Published in:

01-12-2021 | Mastectomy | Original Article

Comparison of two different surgical strategies for breast cancer patients treated with mastectomy plus sentinel lymph node biopsy

Authors: Xing Zhang, Qian Shen, Yu-Jie Hu

Published in: Updates in Surgery | Issue 6/2021

Abstract

Two separated incisions are generally adopted in breast cancer patients treated by mastectomy plus sentinel lymph node biopsy (SLNB). However, one-incision procedure is also applied in clinical practice. The outcomes of the two different surgical strategies remain unknown. This issue needs to be investigated. The medical records of breast cancer patients who underwent a mastectomy combined with an SLNB were reviewed retrospectively. Group A comprised patients who received a single incision for both the mastectomy and SLNB. Group B comprised patients who received a second incision for the SLNB. Demographics and outcomes were compared between the two groups. There were 280 female patients divided into Groups A (n = 130) and B (n = 150) included in this study. Preoperatively, the two groups were similar in demographics for age, tumor size, tumor location, body mass index, pathologic type, and cancer stage (P > 0.05). Group A showed shorter surgical times (129.5 ± 29.0 vs. 136.7 ± 21.9 min), less postoperative upper limb numbness (12.3% vs. 25.3%), and more harvested sentinel lymph nodes (3.2 ± 1.1 vs. 2.7 ± 1.0) than Group B (P < 0.05). There were no significant differences for intraoperative blood loss, total postoperative drainage amount, hospital stay, upper limb motility, upper limb pain, upper limb edema, number of metastatic sentinel lymph nodes, follow-up time, or recurrent cases (P > 0.05). The one-incision approach for a breast cancer mastectomy plus SLNB has several advantages over the two-incision approach, including a shorter surgical time, decreased upper limb numbness, and the harvesting of more sentinel lymph nodes. Further prospective randomized controlled clinical trials should be designed to verify the current findings.

Momenimovahed Z, Salehiniya H (2019) Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Medical Press) 11:151–164. https://doi.org/10.2147/BCTT.S176070CrossRef

Zhou Y, Li Y, Mao F, Zhang J, Zhu Q, Shen S, Lin Y, Zhang X, Liu H, Xiao M, Jiang Y, Sun Q (2019) Preliminary study of contrast-enhanced ultrasound in combination with blue dye vs. indocyanine green fluorescence, in combination with blue dye for sentinel lymph node biopsy in breast cancer. BMC Cancer 19:939. https://doi.org/10.1186/s12885-019-6165-4CrossRefPubMedPubMedCentral

Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Hunt KK, Morrow M, Ballman K (2010) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 252:426–432. https://doi.org/10.1097/SLA.0b013e3181f08f32CrossRefPubMed

Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JH, Orzalesi L, Bouma WH, van der Mijle HC, Nieuwenhuijzen GA, Veltkamp SC, Slaets L, Duez NJ, de Graaf PW, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JW, Belkacemi Y, Petignat P, Schinagl DA, Coens C, Messina CG, Bogaerts J, Rutgers EJ (2014) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15:1303–1310. https://doi.org/10.1016/S1470-2045(14)70460-7CrossRefPubMedPubMedCentral

Morrow M, Khan AJ (2020) Locoregional management after neoadjuvant chemotherapy. J Clin Oncol 38:2281–2289. https://doi.org/10.1200/JCO.19.02576CrossRefPubMedPubMedCentral

Yuan L, Qi X, Zhang Y, Yang X, Zhang F, Fan L, Chen L, Zhang K, Zhong L, Li Y, Gan S, Fu W, Jiang J (2018) Comparison of sentinel lymph node detection performances using blue dye in conjunction with indocyanine green or radioisotope in breast cancer patients: a prospective single-center randomized study. Cancer Biol Med 15:452–460. https://doi.org/10.20892/j.issn.2095-3941.2018.0270CrossRefPubMedPubMedCentral

Papathemelis T, Jablonski E, Scharl A, Hauzenberger T, Gerken M, Klinkhammer-Schalke M, Hipp M, Scharl S (2018) Sentinel lymph node biopsy in breast cancer patients by means of indocyanine green using the Karl Storz VITOM® fluorescence camera. Biomed Res Int 2018:6251468. https://doi.org/10.1155/2018/6251468CrossRefPubMedPubMedCentral

Gao W, Zeng Y, Fei X, Chen X, Shen K (2020) Axillary lymph node and non-sentinel lymph node metastasis among the ACOSOG Z0011 eligible breast cancer patients with invasive ductal, invasive lobular, or other histological special types: a multi-institutional retrospective analysis. Breast Cancer Res Treat 184:193–202. https://doi.org/10.1007/s10549-020-05842-9CrossRefPubMed

Adachi Y, Sawaki M, Hattori M, Yoshimura A, Gondo N, Kotani H, Iwase M, Kataoka A, Onishi S, Sugino K, Terada M, Horisawa N, Mori M, Oze I, Iwata H (2018) Comparison of sentinel lymph node biopsy between invasive lobular carcinoma and invasive ductal carcinoma. Breast cancer (Tokyo, Japan) 25:560–565. https://doi.org/10.1007/s12282-018-0852-xCrossRef

10.

Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn H-J, Thürlimann B, Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017 (2019) De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 30(7):1181. https://doi.org/10.1093/annonc/mdy537CrossRefPubMedPubMedCentral

11.

Piltin MA, Hoskin TL, Day CN, Davis J Jr, Boughey JC (2020) Oncologic outcomes of sentinel lymph node surgery after neoadjuvant chemotherapy for node-positive breast cancer. Ann Surg Oncol 27:4795–4801. https://doi.org/10.1245/s10434-020-08900-0CrossRefPubMed

12.

Lyman GH, Somerfield MR, Giuliano AE (2017) Sentinel lymph node biopsy for patients with early-stage breast cancer: 2016 american society of clinical oncology clinical practice guideline update summary. J Oncol Pract 13:196–198. https://doi.org/10.1200/JOP.2016.019992CrossRefPubMed

13.

Agrawal SK, Hashlamoun I, Karki B, Sharma A, Arun I, Ahmed R (2020) Diagnostic performance of indocyanine green plus methylene blue versus radioisotope plus methylene blue dye method for sentinel lymph node biopsy in node-negative early breast cancer. JCO Glob Oncol 6:1225–1231. https://doi.org/10.1200/GO.20.00165CrossRefPubMed

14.

Kitai T, Inomoto T, Miwa M, Shikayama T (2005) Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer. Breast Cancer 12:211–215. https://doi.org/10.2325/jbcs.12.211CrossRefPubMed

15.

Verbeek FP, Troyan SL, Mieog JS, Liefers GJ, Moffitt LA, Rosenberg M, Hirshfield-Bartek J, Gioux S, van de Velde CJ, Vahrmeijer AL, Frangioni JV (2014) Near-infrared fluorescence sentinel lymph node mapping in breast cancer: a multicenter experience. Breast Cancer Res Treat 143:333–342. https://doi.org/10.1007/s10549-013-2802-9CrossRefPubMed

16.

Guo J, Yang H, Wang S, Cao Y, Liu M, Xie F, Liu P, Zhou B, Tong F, Cheng L, Liu H, Wang S (2017) Comparison of sentinel lymph node biopsy guided by indocyanine green, blue dye, and their combination in breast cancer patients: a prospective cohort study. World J Surg Oncol 15:196. https://doi.org/10.1186/s12957-017-1264-7CrossRefPubMedPubMedCentral

17.

Goonawardena J, Yong C, Law M (2020) Use of indocyanine green fluorescence compared to radioisotope for sentinel lymph node biopsy in early-stage breast cancer: systematic review and meta-analysis. Am J Surg 220:665–676. https://doi.org/10.1016/j.amjsurg.2020.02.001CrossRefPubMed

18.

Qin X, Yang M, Zheng X (2019) Comparative study of indocyanine green combined with blue dye with methylene blue only and carbon nanoparticles only for sentinel lymph node biopsy in breast cancer. Ann Surg Treat Res 97:1–6. https://doi.org/10.4174/astr.2019.97.1.1CrossRefPubMedPubMedCentral

19.

Wu X, Lin Q, Chen G, Lu J, Zeng Y, Chen X, Yan J (2015) Sentinel lymph node detection using carbon nanoparticles in patients with early breast cancer. PLoS ONE 10:e0135714. https://doi.org/10.1371/journal.pone.0135714CrossRefPubMedPubMedCentral

20.

Zhang L, Huang Y, Yang C, Zhu T, Lin Y, Gao H, Yang M, Cheng M, Wang K (2018) Application of a carbon nanoparticle suspension for sentinel lymph node mapping in patients with early breast cancer: a retrospective cohort study. World J Surg Oncol 16:112. https://doi.org/10.1186/s12957-018-1414-6CrossRefPubMedPubMedCentral

21.

Yang SX, Wei WS, Jiang QH, Zhou YF, Qu W, Tu JH, Ou-Yang QW, Zhou ZB, Ding HL, Xie CW (2018) Analysis of 246 sentinel lymph node biopsies of patients with clinical primary breast cancer by application of carbon nanoparticle suspension. J Obstet Gynaecol Res 44:1150–1157. https://doi.org/10.1111/jog.13635CrossRefPubMed

22.

Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas EP, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Wolmark N (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11:927–933. https://doi.org/10.1016/S1470-2045(10)70207-2CrossRefPubMedPubMedCentral

23.

Gill J, Lovegrove R, Naessens K, Pursell R, Cominos T, McCormick C, Umeh H, Courtney S, Smith B (2011) Sentinel lymph node biopsy in breast cancer: an analysis of the maximum number of nodes requiring excision. Breast J 17:3–8. https://doi.org/10.1111/j.1524-4741.2010.01019.xCrossRefPubMed

24.

Sugie T, Ikeda T, Kawaguchi A, Shimizu A, Toi M (2017) Sentinel lymph node biopsy using indocyanine green fluorescence in early-stage breast cancer: a meta-analysis. Int J Clin Oncol 22:11–17. https://doi.org/10.1007/s10147-016-1064-zCrossRefPubMed

25.

Valiveru RC, Agarwal G, Agrawal V, Gambhir S, Mayilvaganan S, Chand G, Mishra A, Agarwal A, Mishra SK (2020) Low-cost fluorescein as an alternative to radio-colloid for sentinel lymph node biopsy-a prospective validation study in early breast cancer. World J Surg 44:3417–3422. https://doi.org/10.1007/s00268-020-05631-xCrossRefPubMed

Title: Comparison of two different surgical strategies for breast cancer patients treated with mastectomy plus sentinel lymph node biopsy
Authors: Xing Zhang
Qian Shen
Yu-Jie Hu
Publication date: 01-12-2021
Publisher: Springer International Publishing
Keywords: Mastectomy
Breast Cancer
Breast Cancer
Incision
Published in: Updates in Surgery / Issue 6/2021
Print ISSN: 2038-131X
Electronic ISSN: 2038-3312
DOI: https://doi.org/10.1007/s13304-021-01109-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Comparison of two different surgical strategies for breast cancer patients treated with mastectomy plus sentinel lymph node biopsy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2021

Personal technique for minimally invasive VATS lobectomy with en-bloc chest wall resection for T3 NSCLC

The innate aptitude’s effect on the surgical task performance: a systematic review

The use of an implemented infection prevention bundle reduces the incidence of surgical site infections after colorectal surgery: a retrospective single center analysis

Jain point: an alternate laparoscopic non-umbilical first blind entry port to avoid vessel, viscera, adhesions and bowel (VVAB)

High-pressure CO2 insufflation is a risk factor for postoperative ileus in patients undergoing TaTME

Trans-vaginal repair of recurrent rectovaginal fistula with interposition of BIO-A Tissue Reinforcement